Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News PDL and Biogen confirm daclizumab reduces MS lesions

PDL and Biogen confirm daclizumab reduces MS lesions

12th October 2007

Biogen Idec and PDL BioPharma have announced new data showing daclizumab to significantly reduce Multiple Sclerosis (MS) lesions in patients receiving interferon beta therapy.

The results were taken from a Phase II study and are set to be presented at the 23rd Congress of the European Committee for Treatment and Research of Multiple Sclerosis (ECTRIMS) in Prague, Czech Republic.

The trial looked at MS patients who continue to have active MS disease while receiving interferon beta therapy.

Patients who received daclizumab 2mg subcutaneously every two weeks showed a statistically significant 72 per cent reduction in the number of new or enlarged gadolinium-enhancing lesions at week 24, compared to patients who were just receiving interferon beta therapy.

Safety and efficacy were further assessed with patients being followed for an additional 48 weeks following the daclizumab treatment period.

Mark A McCamish, chief medical officer at PDL BioPharma, welcomed the results and confirmed the importance of research into monoclonal antibodies like daclizumab.

“We’re very excited to move development of daclizumab forward with our partner Biogen Idec, the acknowledged leader in the MS field.”

Earlier this month, Biogen Idec announced the publication of findings from a preclinical study showing that the anti-Lingo-1 antibody can promote spinal cord remyelination and axonal integrity.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.